Text Size

Maternal KIR and Fetal HLA-C Genes in Recurrent Miscarriages

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Imperial College London.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Imperial College London
ClinicalTrials.gov Identifier:
NCT00180804
First received: September 13, 2005
Last updated: December 13, 2005
Last verified: September 2005
History of Changes
  Purpose

For implantation of developing conceptus, placental cells need to invade mother's uterus to access maternal blood supply in a control manner. We have found a combination of maternal immune genes (the KIR family) and fetal genes (HLA-C) strongly associated with pre-eclampsia where placenta does not implant adequately. The aim of this research is to investigate these two genes family in women suffering with recurrent miscarriages and find a possible link between them.


Condition
Recurrent Miscarriages

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Retrospective/Prospective
Official Title: Combination of Maternal KIR and Fetal HLA-C Genes in Recurrent Miscarriages

Resource links provided by NLM:

MedlinePlus related topics: Miscarriage
U.S. FDA Resources

Further study details as provided by Imperial College London:

Estimated Enrollment: 400
Study Start Date: April 2005
Estimated Study Completion Date: August 2005
Detailed Description:

Little is known about reasons for early pregnancy failures. It is believed that some pathology leading to defective implantation of fetus in maternal uterus may lead to recurrent early miscarriages. This project arises from previous work on pre-eclampsia where we found combination of maternal immune genes (KIR) with their ligand (HLA-C) in the fetus was strongly associated with the disease. We will tissue type the fetus, mother and father in cases of unexplained miscarriages. We hope that genetic findings in recurrent miscarriage will lead to new insights, prevention and treatment.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Couples with 3 or more unexplained miscarriages

Exclusion Criteria:

Previous livebirths, parental karyotypic abnormalities, thrombophilic defects, uterine structural abnormalities

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00180804

Contacts
Contact: Lesley Regan, FRCOG 02078861050 l.regan@imperial.ac.uk

Locations
United Kingdom
St. Mary's Hospital Recruiting
London, United Kingdom, W2 1NY
Contact: Lesley Regan, FRCOG     02078861050     l.regan@imperial.ac.uk    
Sponsors and Collaborators
Imperial College London
Investigators
Principal Investigator: Ashley Moffett, MRCP University of Cambridge, UK
Principal Investigator: Raj Rai, MRCOG Imperial College London
Principal Investigator: Preeti Jindal, MRCOG St. Mary's NHS Trust, London
Principal Investigator: Winnie Lo St. Mary's NHS Trust, London
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00180804     History of Changes
Other Study ID Numbers: 05/MRE02/20
Study First Received: September 13, 2005
Last Updated: December 13, 2005
Health Authority: United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:
Abortion, Spontaneous
Abortion, Habitual
Pregnancy Complications

ClinicalTrials.gov processed this record on May 21, 2013